Implementation Strategies for Monitoring Adherence in Real Time

Study summary

The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedConversational Agent/Chatbot and Usual Care

The study team can explain what participation involves.

Who it may be forLung Cancer · Medication Adherence

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 4, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Abramson Cancer Center at Penn Medicine

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Not applicable
Sponsor: Abramson Cancer Center at Penn Medicine
Interventions being studied: Device: Conversational Agent/Chatbot; Other: Usual Care

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Targeted therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Adult patient (age \> 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.
Patient possession of a mobile device that can send/receive SMS texts
Ability to respond to questions and engage with "Penny" in English
Ability to provide informed consent to participate in the study
Approval from the patient's medical oncologist to be approached

Reasons someone may not be able to joinExclusion criteria

Inability to respond to questions and engage with "Penny" in English
Inability or unwillingness to provide informed consent to participate in the study
Inability to engage with SMS text-messaging platform
Concurrent enrollment in a therapeutic clinical trial
Taking more than one oral targeted therapy or concurrent chemotherapy during the study window
Lack of approval from the patient's oncologist

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 4, 2026. Always confirm current availability with the study team.

View original record ↗